Methods and systems for multi-antibody therapies
The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.
1. A method for administering antibody therapeutic agents to treat an individual for exposure to a Botulinum neurotoxin, the method comprising:
a. administering to the individual at least one binding agent, wherein the binding agent comprises a single-chain antibody (scFv) and has a binding region specific to the Botulinum neurotoxin and has one or more copies of a tag comprising an antibody epitope; and
b. administering to the individual an anti-tag antibody, wherein the anti-tag antibody binds to the one or more copies of the tag of the binding agent and promotes clearance of the Botulinum neurotoxin, thereby treating the individual; and the binding agent binds to the portion of the Botulinum neurotoxin wherein the Botulinum neurotoxin is Botulinum neurotoxin serotype A, and wherein the scFv is encoded by a nucleic acid comprising a nucleotide sequence selected from the group of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NO: 13.
2. The method according to claim 1 , wherein the disease agent target is Botulinum neurotoxin a serotype A, and wherein the scFv comprises an amino acid sequence selected from the group of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14.